T-helper 17 cell polarization in pulmonary arterial hypertension

Chest

Volumn 147, Issue 6, 2015, Pages 1610-1620

  Hautefort, Aurélie ^a,c   Girerd, Barbara ^a,b,c   Montani, David ^a,b,c   Cohen Kaminsky, Sylvia ^a,c   Price, Laura ^d   Lambrecht, Bart N ^e   Humbert, Marc ^a,b,c   Perros, Frédéric ^a,c  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b BICÊTRE HOSPITAL   (France)

^c CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^d ROYAL BROMPTON HOSPITAL   (United Kingdom)

^e GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; CD86 ANTIGEN; DEXAMETHASONE; INTERLEUKIN 12P40; INTERLEUKIN 17; INTERLEUKIN 4; SECONDARY LYMPHOID TISSUE CHEMOKINE; GLUCOCORTICOID;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CELL POLARITY; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; DENDRITIC CELL; DNA METHYLATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LYMPHOCYTE PROLIFERATION; MALE; MONOCYTE DERIVED DENDRITIC CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROMOTER REGION; PULMONARY HYPERTENSION; T LYMPHOCYTE ACTIVATION; TH17 CELL; CASE CONTROL STUDY; CELL CULTURE; CELL PROLIFERATION; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; ANTIGENS, CD40; ANTIGENS, CD86; CASE-CONTROL STUDIES; CELL POLARITY; CELL PROLIFERATION; CELLS, CULTURED; DENDRITIC CELLS; DEXAMETHASONE; FEMALE; GLUCOCORTICOIDS; HUMANS; HYPERTENSION, PULMONARY; IMMUNOPHENOTYPING; MALE; MIDDLE AGED; TH17 CELLS;

EID: 84930893678     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.14-1678     Document Type: Article

References (45)

1. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351(14):1425-1436.
2. Huertas A, Perros F, Tu L, et al. Immune dysregulation and endothelial dysfunction in pulmonary arterial hypertension: a complex interplay. Circulation. 2014;129(12):1332-1340.
3. Dorfmüller P, Humbert M. Progress in pulmonary arterial hypertension pathology: relighting a torch inside the tunnel. Am J Respir Crit Care Med. 2012;186(3):210-212.
4. Price LC, Wort SJ, Perros F, et al. Inflammation in pulmonary arterial hypertension. Chest. 2012;141(1):210-221.
5. Kherbeck N, Tamby MC, Bussone G, et al. The role of inflammation and autoimmunity in the pathophysiology of pulmonary arterial hypertension. Clin Rev Allergy Immunol. 2013;44(1):31-38.
6. Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF. Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol. 2009;297(6):L1013-L1032.
7. West J, Austin E, Fessel JP, Loyd J, Hamid R. Rescuing the BMPR2 signaling axis in pulmonary arterial hypertension. Drug Discov Today. 2014;19(8):1241-1245.
8. Song Y, Coleman L, Shi J, et al. Inflammation, endothelial injury, and persistent pulmonary hypertension in heterozygous BMPR2-mutant mice. Am J Physiol Heart Circ Physiol. 2008;295(2):H677-H690.
9. Sanchez O, Marcos E, Perros F, et al. Role of endothelium-derived CC chemokine ligand 2 in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2007;176(10):1041-1047.
10. Soon E, Holmes AM, Treacy CM, et al. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation. 2010;122(9):920-927.
11. Huertas A, Tu L, Gambaryan N, et al. Leptin and regulatory T-lymphocytes in idiopathic pulmonary arterial hypertension. Eur Respir J. 2012;40(4):895-904.
12. Cracowski JL, Chabot F, Labarère J, et al. Proinflammatory cytokine levels are linked to death in pulmonary arterial hypertension. Eur Respir J. 2014;43(3):915-917.
13. Price LC, Caramori G, Perros F, et al. Nuclear factor κ-B is activated in the pulmonary vessels of patients with end-stage idiopathic pulmonary arterial hypertension. PLoS ONE. 2013;8(10):e75415.
14. Perros F, Dorfmüller P, Montani D, et al. Pulmonary lymphoid neogenesis in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2012;185(3):311-321.
15. Ogawa A, Nakamura K, Mizoguchi H, et al. Prednisolone ameliorates idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2011;183(1):139-140.
16. Sanchez O, Sitbon O, Jaïs X, Simonneau G, Humbert M. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest. 2006;130(1):182-189.
17. Cohen-Kaminsky S, Hautefort A, Price L, Humbert M, Perros F. Inflammation in pulmonary hypertension: what we know and what we could logically and safely target first. Drug Discov Today. 2014;19(8):1251-1256.
18. Lambrecht BN, Hammad H. The role of dendritic and epithelial cells as master regulators of allergic airway inflammation. Lancet. 2010;376(9743):835-843.
19. Perros F, Dorfmüller P, Souza R, et al. Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension. Eur Respir J. 2007;29(3):462-468.
20. Kim SJ, Diamond B. Modulation of tolerogenic dendritic cells and autoimmunity [published online ahead of print April 18, 2014]. Semin Cell Dev Biol.
21. Ganguly D, Haak S, Sisirak V, Reizis B. The role of dendritic cells in autoimmunity. Nat Rev Immunol. 2013;13(8):566-577.
22. Quintana FJ, Yeste A, Mascanfroni ID. Role and therapeutic value of dendritic cells in central nervous system autoimmunity. Cell Death Differ. 2015;22(2):215-224.
23. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006;173(9):1023-1030.
24. Hu J, Kinn J, Zirakzadeh AA, et al. The effects of chemotherapeutic drugs on human monocyte-derived dendritic cell differentiation and antigen presentation. Clin Exp Immunol. 2013;172(3):490-499.
25. Selmi C. Autoimmunity in 2013. Clin Rev Allergy Immunol. 2014;47(1):100-109.
26. Perros F, Cohen-Kaminsky S, Dorfmüller P, et al. Inflammation in pulmonary arterial hypertension. In: Abraham D, Handler C, Dashwood M, Coghlan G, eds. Translational Vascular Medicine. London, England: Springer London; 2012:213-229.
27. Quintero OL, Amador-Patarroyo MJ, Montoya-Ortiz G, Rojas-Villarraga A, Anaya JM. Autoimmune disease and gender: plausible mechanisms for the female predominance of autoimmunity. J Autoimmun. 2012;38(2-3):J109-J119.
28. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010;122(2):156-163.
29. Dib H, Tamby MC, Bussone G, et al. Targets of anti-endothelial cell antibodies in pulmonary hypertension and scleroderma. Eur Respir J. 2012;39(6):1405-1414.
30. Tamby MC, Chanseaud Y, Humbert M, et al. Anti-endothelial cell antibodies in idiopathic and systemic sclerosis associated pulmonary arterial hypertension. Thorax. 2005;60(9):765-772.
31. Terrier B, Tamby MC, Camoin L, et al. Identification of target antigens of antifibroblast antibodies in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2008;177(10):1128-1134.
32. Bussone G, Tamby MC, Calzas C, et al. IgG from patients with pulmonary arterial hypertension and/or systemic sclerosis binds to vascular smooth muscle cells and induces cell contraction. Ann Rheum Dis. 2012;71(4):596-605.
33. Colvin KL, Cripe PJ, Ivy DD, Stenmark KR, Yeager ME. Bronchus-associated lymphoid tissue in pulmonary hypertension produces pathologic autoantibodies. Am J Respir Crit Care Med. 2013;188(9):1126-1136.
34. Neyt K, Perros F, GeurtsvanKessel CH, Hammad H, Lambrecht BN. Tertiary lymphoid organs in infection and autoimmunity. Trends Immunol. 2012;33(6):297-305.
35. Rangel-Moreno J, Hartson L, Navarro C, Gaxiola M, Selman M, Randall TD. Inducible bronchus-associated lymphoid tissue (iBALT) in patients with pulmonary complications of rheumatoid arthritis. J Clin Invest. 2006;116(12):3183-3194.
36. Rangel-Moreno J, Carragher DM, de la Luz Garcia-Hernandez M, et al. The development of inducible bronchus-associated lymphoid tissue depends on IL-17. Nat Immunol. 2011;12(7):639-646.
37. Campbell DJ, Koch MA. Phenotypical and functional specialization of FOXP3+ regulatory T cells. Nat Rev Immunol. 2011;11(2):119-130.
38. Crome SQ, Lang PA, Lang KS, Ohashi PS. Natural killer cells regulate diverse T cell responses. Trends Immunol. 2013;34(7):342-349.
39. Berzins SP, Smyth MJ, Baxter AG. Presumed guilty: natural killer T cell defects and human disease. Nat Rev Immunol. 2011;11(2):131-142.
40. Perros F, Cohen-Kaminsky S, Humbert M. Understanding the role of CD4 + CD25(high) (so-called regulatory) T cells in idiopathic pulmonary arterial hypertension. Respiration. 2008;75(3):253-256.
41. Ormiston ML, Chang C, Long LL, et al. Impaired natural killer cell phenotype and function in idiopathic and heritable pulmonary arterial hypertension. Circulation. 2012;126(9):1099-1109.
42. Perros F, Cohen-Kaminsky S, Gambaryan N, et al. Cytotoxic cells and granulysin in pulmonary arterial hypertension and pulmonary veno-occlusive disease. Am J Respir Crit Care Med. 2013;187(2):189-196.
43. Isono F, Fujita-Sato S, Ito S. Inhibiting RORγt/Th17 axis for autoimmune disorders. Drug Discov Today. 2014;19(8):1205-1211.
44. Gerosa F, Baldani-Guerra B, Lyakh LA, et al. Differential regulation of interleukin 12 and interleukin 23 production in human dendritic cells. J Exp Med. 2008;205(6):1447-1461.
45. Wang Q, Franks HA, Porte J, et al. Novel approach for interleukin-23 up-regulation in human dendritic cells and the impact on T helper type 17 generation. Immunology. 2011;134(1):60-72.